ElutiaELUT
ELUT
About: Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Employees: 54
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
400% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 3
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
12% more funds holding
Funds holding: 26 [Q2] → 29 (+3) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
5.43% less ownership
Funds ownership: 46.4% [Q2] → 40.98% (-5.43%) [Q3]
13% less capital invested
Capital invested by funds: $53.4M [Q2] → $46.7M (-$6.7M) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
107%
upside
Avg. target
$10
107%
upside
High target
$10
107%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Ross Osborn 49% 1-year accuracy 23 / 47 met price target | 107%upside $10 | Overweight Reiterated | 15 Nov 2024 |
Financial journalist opinion
Negative
Zacks Investment Research
1 week ago
Are Medical Stocks Lagging ELUTIA INC (ELUT) This Year?
Here is how Elutia Inc. (ELUT) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Neutral
Seeking Alpha
1 month ago
Elutia Inc. (ELUT) Q3 2024 Earnings Call Transcript
Elutia Inc. (NASDAQ:ELUT ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Matt Steinberg – FINN Partners Randy Mills – Chief Executive Officer Matt Ferguson – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Ross Osborn – Cantor Fitzgerald Operator Greetings. Welcome to the Elutia Third Quarter 2024 Financial Results Call.
Neutral
GlobeNewsWire
1 month ago
Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30
SILVER SPRING, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XVII Conference in Los Angeles on Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET).
Neutral
GlobeNewsWire
3 months ago
Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company's Antibiotic-Eluting BioEnvelope for Implantable Devices
EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model
Neutral
GlobeNewsWire
3 months ago
Elutia Celebrates First Year
Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, is celebrating its one-year anniversary and the team that made it possible.
Neutral
GlobeNewsWire
3 months ago
Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators
SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world's first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac Electrophysiology Fellowship at East Carolina University Health Medical Center in Greenville, North Carolina.
Neutral
GlobeNewsWire
3 months ago
Elutia to Participate in Upcoming Investor Conferences
SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York:
Neutral
GlobeNewsWire
4 months ago
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now
MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.
Neutral
Seeking Alpha
4 months ago
Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript
Elutia Inc. (NASDAQ:ELUT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners, IR Randy Mills - President and CEO Matt Ferguson - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Operator Greetings. Welcome to the Elutia Second Quarter 2024 Financial Results Call.
Neutral
GlobeNewsWire
4 months ago
Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations
SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries.
Charts implemented using Lightweight Charts™